NXTCNasdaqPharmaceutical PreparationsFiscal year ends December 31
NextCure, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$5.67−0.57 (-9.13%)
Close on Oct 19, 2026
- Market cap
- $30.11M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
37.9%
2M of 5M shares
Institutional holders
30
11 new, 7 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
13 buys · 1 sales
Net bought $1.53M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| ADAR1 Capital Management, LLC | 722,419 | 15.80% | 13G (passive) | Jul 31, 2026 |
| Neil Shahrestani | 502,672 | 9.99% | 13G (passive) amendment | Jun 30, 2026 |
| Affinity Asset Advisors, LLC | 348,607 | 9.99% | 13G (passive) amendment | Jan 22, 2026 |
| Simcere Zaiming, Inc. | 338,636 | 12.70% | 13G (passive) | Jun 20, 2025 |
| Ren Jinsheng | 338,636 | 9.40% | 13G (passive) amendment | Dec 31, 2025 |
| Adage Capital Management, L.P. | 277,202 | 7.67% | 13G (passive) | Jun 30, 2026 |
| Michael Cho | 274,073 | 6.40% | 13G (passive) amendment | Jun 30, 2026 |
| Sofinnova Management IX, L.L.C. ("SM IX") | 222,654 | 7.10% | 13D (active) amendment | Dec 19, 2025 |
| Devesh Gandhi | 176,057 | 5.02% | 13G (passive) | Dec 31, 2025 |
| Matthew Sesterhenn | 173,861 | 6.50% | 13G (passive) | Oct 21, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of NXTC | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Ikarian Capital, LLC | 288,303 | 6.30% | $461.28K | +50,000 | 0.05% |
| Adage Capital Partners Gp, L.L.C. | 277,202 | 6.06% | $443.52K | New | 0.00% |
| Sofinnova Investments, Inc. | 222,654 | 4.86% | $356.25K | – | 0.02% |
| Renaissance Technologies LLC | 171,202 | 3.74% | $273.92K | +110,668 | 0.00% |
| Vanguard Capital Management LLC | 156,842 | 3.43% | $250.95K | −3,631 | 0.00% |
| Millennium Management LLC | 88,112 | 1.92% | $140.98K | New | 0.00% |
| Boothbay Fund Management, LLC | 84,687 | 1.85% | $135.50K | +15,070 | 0.00% |
| Squadron Capital Management LLC | 64,464 | 1.41% | $103.14K | −200,536 | 0.03% |
| Verdad Advisers, LP | 60,451 | 1.32% | $96.72K | +17,496 | 0.09% |
| Pfizer Inc | 44,347 | 0.97% | $72.97K | −109,007 | 0.04% |
| Affinity Asset Advisors, LLC | 41,960 | 0.92% | $67.14K | −199,866 | 0.00% |
| BlackRock, Inc. | 37,348 | 0.82% | $59.76K | +9,555 | 0.00% |
| Hrt Financial LP | 36,450 | 0.80% | $58 | New | 0.00% |
| Jane Street Group, LLC | 32,725 | 0.71% | $52.36K | New | 0.00% |
| Geode Capital Management, LLC | 29,905 | 0.65% | $47.86K | −1,187 | 0.00% |
| Cardiff Park Advisors, LLC | 21,833 | 0.48% | $34.93K | – | 0.00% |
| Acadian Asset Management LLC | 18,982 | 0.41% | $30 | – | 0.00% |
| Vanguard Fiduciary Trust Co | 16,134 | 0.35% | $25.81K | +119 | 0.00% |
| Nomura Asset Management International Inc. | 12,500 | 0.27% | $20.00K | New | 0.00% |
| Virtu Financial LLC | 10,991 | 0.24% | $18 | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 30 | 2M | 37.9% | 11 / 8 | 5 / 7 | 1M | 1M |
| Q1 2026 | 26 | 2M | 47.4% | 7 / 3 | 4 / 4 | 0M | 0M |
| Q4 2025 | 24 | 2M | 41.5% | 10 / 5 | 4 / 2 | 1M | 0M |
| Q3 2025 | 16 | 1M | 18.3% | 16 / 0 | 0 / 0 | 1M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of NXTC | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 123,276 | 2.69% | $197.24K | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 33,566 | 0.73% | $53.71K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 16,250 | 0.36% | $100.75K | 0.00% | May 31, 2026 |
| Nomura Healthcare Fund | 12,500 | 0.27% | $20.00K | 0.00% | Jun 30, 2026 |
| iShares Micro-Cap ETF | 9,851 | 0.22% | $15.76K | 0.00% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 3,997 | 0.09% | $24.78K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 3,634 | 0.08% | $22.53K | 0.00% | May 31, 2026 |
| Ultra-Small Company Market Fund | 3,000 | 0.07% | $4.80K | 0.00% | Jun 30, 2026 |
| Fidelity Nasdaq Composite Index Fund | 2,047 | 0.04% | $12.69K | 0.00% | May 31, 2026 |
| 1290 VT Micro Cap Portfolio | 741 | 0.02% | $1.19K | 0.00% | Jun 30, 2026 |
| Diversified Equity Alpha Master Portfolio | 689 | 0.02% | $1.10K | 0.00% | Jun 30, 2026 |
| Dimensional U.S. Core Equity 2 ETF | 59 | 0.00% | $245 | 0.00% | Jul 31, 2026 |
| U.S. Micro Cap Portfolio | 22 | 0.00% | $91 | 0.00% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Michael Richman | President & CEO, Director | 385,869 | 8.43% | Feb 3, 2026 |
| Udayan Guha | Chief Medical Officer | – | – | Feb 3, 2026 |
| Kevin G. Shaw | Sr VP, General Counsel | – | – | Feb 3, 2026 |
| Sourav Kundu | Sr VP, Dev. & Mfg. | – | – | Feb 3, 2026 |
| Timothy Mayer | Chief Operating Officer | – | – | Feb 3, 2026 |
| Steven P. Cobourn | Chief Financial Officer | – | – | Feb 3, 2026 |
| Sol Langermann | Chief Scientific Officer | 37,342 | 0.82% | Feb 3, 2025 |
| Elaine V. Jones | Director | – | – | Jun 22, 2026 |
| Anne Elizabeth Borgman | Director | – | – | Jun 22, 2026 |
| Ellen Feigal | Director | – | – | Jun 22, 2026 |
| Stephen W. Webster | Director | – | – | Jun 22, 2026 |
| John G. Houston | Director | – | – | Jun 22, 2026 |
| David S. Kabakoff | Director | 62,237 | 1.36% | Jun 22, 2026 |
| Simcere Zaiming, Inc. | – | 338,636 | 7.40% | Aug 12, 2026 |
| Jinsheng Ren | – | 338,636 | 7.40% | Aug 12, 2026 |
| Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. | – | 308,636 | 6.74% | Aug 12, 2026 |
| Hainan Simcere Zaiming Pharmaceutical Co., Ltd. | – | – | – | Aug 12, 2026 |
| Renhong Tang | – | – | – | Aug 12, 2026 |
| Pharmaceutical Group Ltd Simcere | – | – | – | Aug 12, 2026 |
| Daniel Schneeberger | 10% owner | – | – | Aug 3, 2026 |
| ADAR1 Capital Management, LLC | 10% owner | 714,416 | 15.61% | Aug 3, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. – | Aug 10, 2026 | Sale | −30,000 | $6.16 | $184.80K | 308,636 |
| ADAR1 Capital Management, LLC 10% owner | Jul 31, 2026 | Buy | +25,000 | $4.98 | $124.50K | 714,416 |
| ADAR1 Capital Management, LLC 10% owner | Jul 31, 2026 | Buy | +3,300 | $4.98 | $16.43K | 689,416 |
| ADAR1 Capital Management, LLC 10% owner | Jul 31, 2026 | Buy | +8,003 | $4.80 | $38.41K | 722,419 |
| ADAR1 Capital Management, LLC 10% owner | Jul 30, 2026 | Buy | +100,000 | $4.90 | $490.00K | 608,266 |
| ADAR1 Capital Management, LLC 10% owner | Jul 30, 2026 | Buy | +77,850 | $4.96 | $386.14K | 686,116 |
| ADAR1 Capital Management, LLC 10% owner | Jul 30, 2026 | Buy | +25,000 | $4.81 | $120.25K | 508,266 |
| ADAR1 Capital Management, LLC 10% owner | Jul 30, 2026 | Buy | +20,000 | $5.00 | $100.00K | 483,266 |
| ADAR1 Capital Management, LLC 10% owner | Jul 30, 2026 | Buy | +20,000 | $5.00 | $100.00K | 463,266 |
| ADAR1 Capital Management, LLC 10% owner | Jul 30, 2026 | Buy | +50,000 | $4.97 | $248.50K | 443,266 |
| ADAR1 Capital Management, LLC 10% owner | Jul 29, 2026 | Buy | +1,600 | $5.00 | $8.00K | 393,266 |
| ADAR1 Capital Management, LLC 10% owner | Jul 29, 2026 | Buy | +1,810 | $5.00 | $9.05K | 391,666 |
| ADAR1 Capital Management, LLC 10% owner | Jul 28, 2026 | Buy | +6,400 | $4.95 | $31.68K | 389,856 |
| ADAR1 Capital Management, LLC 10% owner | Jul 27, 2026 | Buy | +7,798 | $5.00 | $38.99K | 383,456 |
| Kevin N. Heller Chief Medical Officer | Jul 14, 2020 | Option exercise | +27,229 | $1.77 | $48.20K | 49,011 |
| Linda Liu SVP, Research | Nov 27, 2019 | Option exercise | +20,745 | $1.21 | $25.10K | 55,234 |
| Linda Liu SVP, Research | Nov 27, 2019 | Option exercise | +34,489 | $0.48 | $16.55K | 34,489 |
| Sofinnova Venture Partners IX, L.P. 10% owner | Nov 15, 2019 | Buy | +150,000 | $36.75 | $5.51M | 2,671,856 |
| Sofinnova Management IX, L.L.C. 10% owner | May 13, 2019 | Conversion | +464,599 | – | – | 743,358 |
| Sofinnova Management IX, L.L.C. 10% owner | May 13, 2019 | Conversion | +908,785 | – | – | 1,652,143 |
| Sofinnova Management IX, L.L.C. 10% owner | May 13, 2019 | Conversion | +469,713 | – | – | 2,121,856 |
| Sofinnova Management IX, L.L.C. 10% owner | May 13, 2019 | Conversion | +278,759 | – | – | 278,759 |
| Sofinnova Management IX, L.L.C. 10% owner | May 13, 2019 | Buy | +400,000 | $15.00 | $6.00M | 2,521,856 |
| Stella Xu Director | May 13, 2019 | Buy | +125,000 | $15.00 | $1.88M | 1,103,570 |
| Stella Xu Director | May 13, 2019 | Conversion | +978,570 | – | – | 978,570 |
| Timothy M. Shannon Director | May 13, 2019 | Buy | +50,000 | $15.00 | $750.00K | 2,254,442 |
| Timothy M. Shannon Director | May 13, 2019 | Conversion | +445,866 | – | – | 445,866 |
| Timothy M. Shannon Director | May 13, 2019 | Conversion | +743,110 | – | – | 1,188,976 |
| Timothy M. Shannon Director | May 13, 2019 | Conversion | +729,599 | – | – | 1,918,575 |
| Timothy M. Shannon Director | May 13, 2019 | Conversion | +285,867 | – | – | 2,204,442 |
| Capital GP VI LLC OrbiMed Director, 10% owner | May 13, 2019 | Buy | +350,000 | $15.00 | $5.25M | 2,711,013 |
| Capital GP VI LLC OrbiMed Director, 10% owner | May 13, 2019 | Conversion | +442,438 | – | – | 2,361,013 |
| Capital GP VI LLC OrbiMed Director, 10% owner | May 13, 2019 | Conversion | +445,866 | – | – | 445,866 |
| Capital GP VI LLC OrbiMed Director, 10% owner | May 13, 2019 | Conversion | +743,110 | – | – | 1,188,976 |
| Capital GP VI LLC OrbiMed Director, 10% owner | May 13, 2019 | Conversion | +729,599 | – | – | 1,918,575 |
| Alexandria Venture Investments, LLC 10% owner | May 13, 2019 | Conversion | +197,993 | – | – | 197,993 |
| Chau Quang Khuong Director | May 13, 2019 | Conversion | +442,438 | – | – | 2,361,013 |
| Chau Quang Khuong Director | May 13, 2019 | Buy | +350,000 | $15.00 | $5.25M | 2,711,013 |
| Chau Quang Khuong Director | May 13, 2019 | Conversion | +445,866 | – | – | 445,866 |
| Chau Quang Khuong Director | May 13, 2019 | Conversion | +743,110 | – | – | 1,188,976 |
| Chau Quang Khuong Director | May 13, 2019 | Conversion | +729,599 | – | – | 1,918,575 |
| X. L.P. Canaan 10% owner | May 13, 2019 | Conversion | +743,110 | – | – | 1,188,976 |
| X. L.P. Canaan 10% owner | May 13, 2019 | Conversion | +285,867 | – | – | 2,204,442 |
| X. L.P. Canaan 10% owner | May 13, 2019 | Conversion | +729,599 | – | – | 1,918,575 |
| X. L.P. Canaan 10% owner | May 13, 2019 | Conversion | +445,866 | – | – | 445,866 |
| X. L.P. Canaan 10% owner | May 13, 2019 | Buy | +50,000 | $15.00 | $750.00K | 2,254,442 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.